CTLA4 and melanoma: In 2020, Brown, LJ et al. conducted a study of 55 patients with advanced melanoma (stages III–IV) and preexisting SAID treated with combination anti–PD-1 (nivolumab) plus anti–CTLA-4 (ipilimumab).